CA - HLS Therapeutics Q2 GAAP loss per share widens revenue misses August, 11 2022 07:12 AM CA Inc. HLS Therapeutics press release ( OTCPK:HLTRF ): Q2 GAAP EPS of -$0.28 (vs. -$0.07 Y/Y). Revenue of $15.53M (+3.9% Y/Y) misses by $1.27M . For further details see: HLS Therapeutics Q2 GAAP loss per share widens, revenue misses